Aug 15 (Reuters) - Galecto Inc said on Tuesday it will dicontinue development of its lung disease treatment after it failed to meet its primary goal in a mid-stage study. (Reporting by Sriparna Roy in Bengaluru; Editing by Arun Koyyur)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7101 USD | 0.00% | +5.12% | -1.38% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.38% | 19.25M | |
+10.44% | 106B | |
+0.82% | 104B | |
+6.72% | 23.25B | |
-13.89% | 22.5B | |
-6.64% | 18.7B | |
-37.26% | 17.95B | |
-10.98% | 16.99B | |
+8.67% | 14.26B | |
+41.08% | 12.76B |
- Stock Market
- Equities
- GLTO Stock
- News Galecto, Inc.
- Galecto to discontinue development of lung disease treatment